Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Group 1:~* Diagnosed with RA, PsA, axSpA, SLE or AT and currently treated with either conventional synthetic disease modifying antirheumatic drugs (csDMARDs), biologic disease modifying antirheumatic drugs (bDMARDs), targeted synthetic disease modifying antirheumatic drugs (tsDMARDs) or prednisolone.~* Diagnosed with COVID-19 verified by Polymerase Chain Reaction (PCR) or other accepted methods and hospitalized.~* NOT diagnosed with disease known to cause either immunodeficiency or modification (Human Immunodeficiency Virus \[HIV\], lymphoproliferative disease etc.).~* Patients (≥18 years).~* Ability and willingness to give written informed consent.~* Ability to cooperate with research staff.~Group 2:~* NOT diagnosed with an inflammatory disease~* NOT treated with either csDMARDs, bDMARDs, tsDMARDs during the past 6 months or current oral prednisolone treatment.~* Diagnosed with COVID-19 verified by PCR or other accepted methods and hospitalized.~* NOT diagnosed with disease known to cause either immunodeficiency or modification (HIV, lymphoproliferative disease etc.).~* Patients (≥18 years).~* Ability and willingness to give written informed consent.~* Ability to cooperate with research staff.~Group 3:~* Diagnosed with RA, PsA, axSpA, SLE or AT and currently treated with either csDMARDs, bDMARDs, tsDMARDs or prednisolone.~* NOT hospitalised due to a COVID-19 infection.~* NOT diagnosed with disease known to cause either immunodeficiency or modification (HIV, lymphoproliferative disease etc.).~* Patients (≥18 years).~* Ability and willingness to give written informed consent.~* Ability to cooperate with research staff.~Group 4:~* Healthy subjects from the Danish Blood Donors.~* Patients (≥18 years).~* NOT diagnosed with an inflammatory disease.~* NOT treated with either csDMARDs, bDMARDs, tsDMARDs during the past 6 months or current oral prednisolone treatment.~* NOT hospitalised due to a COVID-19 infection.~* Ability and willingness to give written informed consent.~* Ability to cooperate with research staff.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: None): Patients with inflammatory rheumatic diseases who are hospitalised due to a COVID-19 infection
- Group 2 (Type: None): Patients without inflammatory diseases who are hospitalised due to a COVID-19 infection
- Group 3 (Type: None): Patients with inflammatory rheumatic diseases who are having routine blood samples taken under the COVID-19 epidemic after inclusion and who have NOT been hospitalised due to a COVID-19 infection
- Group 4 (Type: None): Healthy subjects from the Danish Blood Donors have NOT been hospitalised due to a COVID-19 infection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues